
2025 in review: Celebrating biotech breakthroughs and key milestones with our clients
Reflecting on 2025, the biotech industry considerably advanced in gene editing, oncology, and AI-driven drug discovery and saw increased M&A activity. We also witnessed a notable shift from oncology innovations beginning to influence treatments in immunology and autoimmune diseases. As the year draws to a close, we’re proud to celebrate





